A recent study suggests that people who discontinue popular GLP-1 drugs like Wegovy and Mounjaro tend to recover shed pounds far faster than those who stop traditional diet and exercise plans.
Published data in a major health publication demonstrates that while overweight individuals frequently drop a large proportion of their total mass while undergoing treatment, the weight is regained at an estimated rate of nearly a kilo each month after stopping.
"Users using such treatments must be informed of the potential of fast rebound weight gain when the medication concludes," cautioned lead investigator Dr. Susan Jebb.
Such speed of regain implies a reversion to starting weight in about 18 months.
Comparing Treatments
The research, which examined 37 of studies involving over 9,000 of participants, compared the effects of GLP-1 agonists with older methods.
Scientists note that people who shed pounds through lifestyle changes alone generally experience a less rapid weight regain—around 100 grams monthly—post-intervention.
Understanding the Rapid Rebound
Nutrition scientists propose the way of the jabs explains the heightened regain.
These medications mimic a natural hormone called GLP-1, which helps regulate hunger.
"Sustained high doses of GLP-1 concentrations far above than normal may cause the system to produce less of its own natural hormone, and may also lessen sensitivity to its actions," noted Dr. Adam Collins, a nutrition expert.
"Withdrawal of this GLP-1 'fix' leads to hunger is no longer kept in check, making excessive eating a significant risk."
A Chronic Disease?
Medical guidelines suggest the jabs for individuals with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Many experts argue that, due to the high risk of weight regain, the therapy should be considered long-term.
This perspective is echoed by pharmaceutical companies, who say that the findings "highlight the chronic nature of obesity," comparing it to managing diseases like high blood pressure.
User Accounts
Individuals who have come off the medication report a sudden return of appetite.
"It was like a switch that goes on and you become extremely hungry," described one woman.
This challenge is worsened if patients have not adopted lasting lifestyle or habit changes during therapy.
Growing Interest
Recent estimates indicate that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire continuing to grow.
- Adoption is more common among females compared to males.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, experts emphasize that while GLP-1 drugs are effective tools for weight loss, they are not a permanent solution and maintained weight loss likely depends on combined behavioural changes.
